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Background: We test the hypothesis that intra-coronary tacrolimus administration can limit infarct size and
preserve left ventricular ejection fraction (LVEF) after acute myocardial infarction (AMI) through ligating left anterior
descending coronary artery (LAD) in mini-pigs.
Methods: Twelve male mini-pigs were randomized into AMI-saline (MI-only) group and AMI-tacrolimus (MI-Tac)
group that received intra-coronary saline (3.0 mL) and tacrolimus (0.5 mg in 2.5 mL saline) injection, respectively,
beyond site of ligation 30 minutes after LAD occlusion.
Results: Larger infarct area was noted in MI-only group (p< 0.001). Inflammatory biomarkers at protein [oxidative stress,
tumor necrotic factor-α, nuclear factor-κB], gene (matrix metalloproteinase-9, plasminogen activator inhibitor-1), and
cellular (CD40+, CD68+ inflammatory cells) levels were remarkably higher in MI-only animals (p< 0.01). Conversely, anti-
inflammatory biomarkers at gene level (Interleukin-10), gene and protein level (endothelial nitric oxide synthase), and
anti-oxidant biomarkers at both gene and protein levels [heme oxygenase 1, NAD(P)H:quinone oxidoreductase] were
lower in MI-only group (p< 0.01). Number of apoptotic nuclei and apoptotic biomarkers expressions at gene and
protein levels (Bax, caspase 3) were notably higher, whereas anti-apoptotic biomarkers at gene and protein levels (Bcl-2),
LVEF, and fractional shortening were markedly lower in MI-only group (p< 0.001).
Conclusion: Intra-coronary administration of tacrolimus significantly attenuated infarct size and preserved LV function.Background
Acute myocardial infarction (AMI) is the leading cause
of death of patients hospitalized for cardiovascular dis-
ease [1,2]. Left ventricular (LV) remodeling as a conse-
quence of LV chamber dilatation and pump failure
following AMI, which are adverse factors typically asso-
ciated with infarct size, largely accounts for unfavorable
outcomes [3-5]. The cause of propagation of myocar-
dium from injury to irrepressible death after AMI has
been extensively investigated [6-8]. A body of evidence* Correspondence: lawrence.c.k.sun@gmail.com; han.gung@msa.hinet.net
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reproduction in any medium, provided the orhas suggested that a complicated network linking inflam-
matory reaction, immune response, production of react-
ive oxygen species (ROS), and cascade of complement
activation may account for the phenomenon of “propaga-
tion of myocardium from injury to irrepressible death”
after AMI [9-13].
Tacrolimus is chemically a macrolide. Activation of the
T-cell receptor normally increases intracellular calcium,
which acts via calmodulin to activate calcineurin. Calci-
neurin then dephosphorylates the transcription factor,
i.e. nuclear factor of activated T-cells (NF-AT), which
moves to the nucleus of the T-cell and increases the ac-
tivity of genes coding for interleukin (IL)-2 and related
cytokines. Tacrolimus prevents the dephosphorylation of
NF-AT [14] through reducing the peptidyl-prolyl isom-
erase activity by binding to the immunophilin FKBP12
(i.e. FK506 binding protein) to create a new complex.
This FKBP12-FK506 complex interacts with and inhibitstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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transduction and IL-2 transcription [15]. Although the
action of tacrolimus is similar to that of cyclosporine,
studies have shown that tacrolimus had significantly
greater 6-year graft survival and a higher projected graft
half-life than those receiving cyclosporin [16].
Clinical observational and experimental studies have
previously shown that cyclosporine therapy effectively
reduced LV infarction size and preserved LV function
after AMI [17,18]. In view of the fact that immune and
inflammatory reactions are one of the major contribu-
tors to death of cardiomyocytes after AMI [6-13,17] and
that tacrolimus is a more potent immunosuppressant
compared to cyclosporine, we propose that tacrolimus
may limit the extent of myocardial infarction and im-
prove LV function in the setting of AMI. To test the hy-
pothesis, we administered tacrolimus through the
coronary arterial system in an acute left anterior des-
cending artery (LAD) occlusion-induced mini-pig AMI
model and assessed the differences in LV infarction size,
viability of myocardium, and LV function as compared
with the animals without treatment.
Methods
Ethics
All animal experimental procedures were approved by
the Institute of Animal Care and Use Committee at our
institute and performed in accordance with the Guide
for the Care and Use of Laboratory Animals (NIH publi-
cation No. 85–23, National Academy Press, Washington,
DC, USA, revised 1996).
Animal model of AMI and rationale of drug dosage
Each male mini-pig (Taitung Animal Propagation Station,
Livestock Research Institute, Taiwan), weighing 16–18 kg,
was anesthetized by intramuscular injection of ketamine
(15 mg/kg) and maintained in anesthetized condition
using an inhalation of 1.5% isoflurane for the whole pro-
cedure. After being shaved on the chest, the mini-pig was
placed in supine position on a warming pad at 37 °C and
then received endotracheal intubation with positive-pres-
sure ventilation (180 mL/min) with room air using a venti-
lator support (Sn: Q422ZO, SIMS PneuPAC, Ltd.) during
the procedure. Electrocardiogram (ECG) monitor and de-
fibrillator were connected to the chest wall of each mini-
pig. One ample of amiodarone (150 mg) was intravenously
given to each animal before the AMI-induction procedure
to prevent the occurrence of malignant arrhythmia.
Under sterile conditions, the heart was exposed through
mid-thoracotomy. The pericardium was gently removed
and the mid-portion of LAD was ligated with 5–0 prolene
suture just distal to the first diagonal branch. Regional myo-
cardial ischemia is confirmed by typical changes in wave-
form on ECG monitor and the observation of rapiddiscoloration of myocardium from pink to gray over the an-
terior surface of left ventricle, together with the rapid devel-
opment of akinesia and dilatation of at-risk area. AMI was
confirmed by complete ECG following the procedure.
Mid-LAD ligations were performed in 16 mini-pigs.
Two mini-pigs in each group succumbed to either ven-
tricular tachycardia or ventricular fibrillation even after
defibrillation. The remaining 12 mini-pigs recruited for
this study were then categorized into AMI plus normal
saline treatment (MI-only) group (n = 6) and AMI plus
tacrolimus therapy (MI-Tac) group (n = 6). For the pur-
pose of comparison at molecular-cellular levels, normal
cardiac tissues were obtained from a group of six mini-
pigs without receiving any treatment that served as the
normal controls (NC).
To determine the optimal drug dosage for maximal ef-
ficacy and acceptable safety, three different dosages of
tacrolimus were adopted for pilot study, including: 1)
1.0 mg; 2) 0.5 mg; and 3) 0.25 mg. Each dosage was tried
on two mini-pigs. The highest dosage induced fatal ma-
lignant ventricular tachyarrhythmia, whereas the second
and third dosages were found to be safe. Since the infarct
size was remarkably smaller in animals receiving the sec-
ond dosage compared with the third one, the second
dosage (i.e. 0.5 mg/kg) was utilized in the current study.
By 30 minutes after LAD ligation, intra-coronary injec-
tions of physiological saline (3.0 mL) in MI-only group
and tacrolimus (0.5 mg in 2.5 mL physiological saline) in
MI-Tac group were given through the LAD beyond the
point of ligation. The muscle and skin of the chest wall
were then closed in layers. The animals were allowed to
recover on the warming pad under close observation.
Functional assessment using echocardiography
The echocardiographic study was performed using
iE33 (Philips Medical System, Bothell, WA) with S5
transducers. The end-systolic dimension (EDS) and
end-diastolic dimension (EDD) were measured at mi-
tral valve and papillary levels of left ventricle.
Recordings were stored for off-line two-dimensional
image analysis using a computer software (Q-lab v6;
Philips Medical System). For each mini-pig, three
consecutive beats were measured and averaged for each
variable. With the animals in a supine position, left ven-
tricular internal dimensions [i.e. end-systolic diameter
(ESD) and end-diastolic diameter (EDD)] were measured
according to the American Society of Echocardiography
leading-edge method using at least three consecutives car-
diac cycles. The LV ejection fraction (LVEF) was calcu-
lated as: LVEF (%) = [(LVEDd3-LVEDs3)/LVEDd3] x 100.
All measurements were performed by an animal cardiolo-
gist blind to treatment and non-treatment groups.
Intra-observer variability was evaluated in a series of six
mini-pigs by one observer who examined the recordings
Table 1 Transthoracic echocardiographic results
Variables Tacrolimus (+) Tacrolimus (−) p-value
Mitral valve level (prior to AMI)
LVEDd (mm) 34.6 ±1.46 35.2 ± 2.32 0.241
LVEDs (mm) 23.4 ±2.32 24.5 ± 1.85 0.457
LVEVd (mL) 50.6 ± 5.3 52.2 ± 5.8 0.316
LVEVs (mL) 16.1 ± 1.4 15.4 ± 1.2 0.459
LVFS (%) 33.6 ± 4.15 35.4 ± 4.63 0.583
LVEF (%) 68.1 ± 1.2 68.1 ± 3.8 0.987
Papillary muscle level (prior to AMI)
LVEDd (mm) 33.4 ± 0.68 34.1 ± 0.75 0.419
LVEDs (mm) 19.4 ± 0.51 19.9 ± 0.59 0.781
LVEVd (mL) 44.0 ± 2.1 46.6 ± 2.3 0.263
LVEVs (mL) 12.0 ± 0.23 12.6 ± 0.54 0.675
LVFS (%) 32.0 ± 2.12 34.1 ± 1.06 0.358
LVEF (%) 72.7 ± 1.3 72.8 ± 1.9 0.885
Mitral valve level (at day 14 after AMI)
LVEDd (mm) 35.7 ± 0.66 36.1 ± 0.91 0.472
LVEDs (mm) 22.3 ± 0.54 23.0 ± 0.94 0.424
LVEVd (mL) 53.2 ± 5.6 55.01 ± 4.1 0.649
LVEVs (mL) 16.0 ± 1.4 18.0 ± 1.2 0.105
LVFS (%) 38.2 ± 3.96 37.0 ± 4.24 0.312
LVEF (%) 68.1 ± 1.2 67.2 ± 1.4 0.645
Papillary muscle level (at day 14 after AMI)
LVEDd (mm) 36.5 ±1.48 37.9 ± 1.67 0.217
LVEDs (mm) 26.2 ± 3.03 31.4 ± 2.76 0.021
LVEVd (mL) 56.6 ±5.8 61.4 ± 6.8 0.263
LVEVs (mL) 26.2 ±8.9 39.6 ± 8.1 0.038
LVFS (%) 30.4 ± 5.94 21.8 ± 6.46 0.046
LVEF (%) 54.2 ±12.6 35.7 ±10.3 0.034
Data are expressed as means ± SD.
(+): with; (−): without.
AMI = acute myocardial infarction; LVEDd = left ventricular end-diastolic
dimension; LVESd = left ventricular end-systolic dimension; LVEVd = left
ventricular end-diastolic volume; LVEVs = left ventricular end-systolic volume;
LVFS = left ventricular fractional shortening; LVEF = left ventricular ejection
fraction.
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variability for LVEF was 2.5 ± 2.1%. All measurements
were performed by a cardiologist blinded to the treatment
and non-treatment groups.
Measurement of infarct area at basal, middle, and apical
levels of left ventricle, and infarcted wall thickness at
papillary muscle level
The heart was removed from each mini-pig following
intravenous injection of an overdose of potassium chlor-
ide. Repeated flushing of the coronary artery with nor-
mal saline for washing out the red blood cells was
performed immediately following heart removal. Three
cross-sections (1 cm in thickness) from the basal, mid-
dle, and apical level, respectively, were used for infarct
area (IA) analysis in IM-only and MI-Tac animals after
being stained with 2% triphenyltetrazolium chloride
(TTC). Briefly, all heart sections were placed on a tray
with a scaled vertical bar to which a digital camera was
attached. The sections were photographed from directly
above at a fixed height. The images obtained were then
analyzed using Image Tool 3 (IT3) image analysis soft-
ware (University of Texas, Health Science Center, San
Antonio, UTHSCSA; Image Tool for Windows, Version
3.0, USA). The calculated IA was expressed as arbitrary
unit for comparison. The rest of the cardiac tissue was
then cut into pieces for specific studies.
To determine the impact of tacrolimus therapy on
thickness of the infarcted LV wall, three cross-sections
of left ventricle at papillary muscle level were made for
each animal and three measurements were recorded on
the thickest regions for each section. The mean thick-
ness was obtained for each animal. All measurements
were performed by a technician blinded to the treatment
and non-treatment groups.
Reverse transcription PCR analysis
Reverse transcription polymerase chain reaction (RT-
PCR) was conducted using LighCycler TaqMan Master
(Roche, Germany) in a single capillary tube according to
the manufacturer’s guidelines for individual component
concentrations. Forward and reverse primers were each
designed based on individual exons of the target gene se-
quence to avoid amplifying genomic DNA.
Isolation of mitochondria
The myocardium from IA was excised and washed with
buffer A (100 mM Tris–HCl, 70 mM sucrose, 10 mM
EDTA and 210 mM mannitol, pH 7.4). Samples were
minced finely in cold buffer A and then incubated for
10 minutes. All samples were homogenized in an additional
3 mL of buffer A using a motor-driven grinder. The
homogenate was centrifuged twice at 700 g for 10 minutes
at 4 °C. The supernatant was again centrifuged at 8,500 gfor 15 minutes, and the pellets were then washed with buf-
fer B (10 mM Tris–HCl, 70 mM sucrose, 1 mM EDTA,
and 230 mM mannitol, pH 7.4). The mitochondria-rich
pellets were then collected and stored at −70 °C.
Western blot analysis
Equal amounts (50μg) of protein extracts were loaded and
separated by SDS-PAGE using 12% acrylamide gradients.
After electrophoresis, the separated proteins were trans-
ferred electrophoretically to a polyvinylidene difluoride
(PVDF) membrane (Amersham Biosciences). Nonspecific
sites were blocked by incubation of the membrane in block-
ing buffer [5% nonfat dry milk in T-TBS (TBS containing
Figure 1 Morphological and histopathological changes in infarcted area. Upper panel) Identification of infarct area (IA) and infarct wall
thickness at papillary level of left ventricle by TTC stain (n = 6 in each group). A) Triphenyltetrazolium chloride (TTC) (2.0%) staining for identifying
IA (green dotted line). B) Significantly larger IA at basal, middle, and apical levels in acute myocardial infarction (AMI) plus normal saline group
than in AMI plus tacrolimus therapy group. C) The wall thickness was significantly higher in AMI + tacrolimus than AMI group. * vs. †, p = 0.036.
Lower panel) The results of H. & E. stain (100x) of the IA at middle level of left ventricle by day 14 after AMI induction (n = 6). D to F) H. & E.
stain showing the IA (yellow arrows) was remarkably larger in MI-only than in MI-Tac group. G) * vs. other groups, P< 0.0001. All statistical
analyses using one-way ANOVA, followed by Tukey’s multiple comparison procedure. Symbols (*, †, {) indicate significance (at 0.05 level). The
Scale bars in right lower corner represent 100 μm. HPF, high-power field.
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incubated with the indicated primary antibodies [Bcl-2 (1:
200, Abcam), Caspase 3 (1: 4000, Abcam), α-smooth
muscle actin (SMA) (1: 1000, Sigma), Bax (1: 1000, Abcam),
connexin (Cx)43 (1: 2000, Chemicon), matrix metallopro-
teinase (MMP)-9 (1: 5000, Abcam), tumor necrotic factor
(TNF)-α (1: 1000, Cell Signaling), nuclear factor (NF)-κB
(1: 600, Abcam), endothelial nitric oxide synthase (eNOS)
(1: 1000, Abcam), NAD(P)H:quinone oxidoreductase
(NQO1) (1: 1000, Abcam), heme oxygenase 1 (HO-1) (1:1000, Abcam), Actin (1: 10000, Chemicon )] for 1 hr at
room temperature. Horseradish peroxidase -conjugated
anti-rabbit immunoglobulin IgG (1: 2000, Cell Signaling)
was used as a second antibody for 1 hr at room
temperature. The washing procedure was repeated eight
times within 1 hr, and immunoreactive bands were visua-
lized by enhanced chemiluminescence (ECL; Amersham
Biosciences) and exposure to Biomax L film (Kodak). For
purposes of quantitation, ECL signals were digitized using
Labwork software (UVP).
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For each mini-pig, six sections (three longitudinal and
three transverse sections of LV myocardium) were ana-
lyzed by an in situ Cell Death Detection Kit [TdT-
FragELTM DNA Fragmentation (Calbiochem)] according
to the manufacture's guidelines. The TUNEL-positive
cells was examined in three randomly chosen high-power
field (400x) and normalized to the total number of cells
divided by 18.Immunohistochemical (IHC) staining for CD40+ and
immunohistofluorescent (IHF) staining for CD68+ cells
and troponin I
Paraffin sections (3 μm thick) were obtained from LV
myocardium of each animal. For identification of CD40+
cells, the sections were initially incubated in 3% hydrogen
peroxide for blocking the action of endogenous peroxid-
ase, and then further processed using BEAT Blocker Kit
(Zymed Company, #50-300) with immersion in solutions
A and B for 30 minutes and 10 minutes, respectively, at
room temperature. Polyclonal rabbit antibodies against
CD40 (dilution 1/100; Spring Bioscience) were then used,
followed by application of SuperPicTureTM Polymer Detec-
tion Kit (Zymed) for 10 minutes at room temperature. Fi-
nally, the sections were counterstained with hematoxylin.
IHF staining was performed using primary antibodies to
recognize CD68+ cells (dilution 1/100; Abcam) or troponin
I (dilution 1/100; Abcam), followed by the application of
FITC-conjugated secondary antibodies (dilution 1/200; mo-
lecular probe). For negative control experiments, the pri-
mary antibodies were omitted.Figure 2 Quantification of viable myocardium and fibrosis of
myocardium in left ventricular infarct area. A to C) Showing
immunofluorescence (400x) troponin-I positive staining of IA for
detecting viable myocardium, demonstrating markedly decreased
distribution of troponin-I positively stained myocardium in IA of AMI
group than that in AMI + tacrolimus group on day 14 following AMI.
D) * vs. other groups, p< 0.0001. (n = 6 for each group) E to G) The
mean fibrotic area in IA was remarkably higher in AMI group than in
AMI + tacrolimus group on Masson Trichrome staining (blue color in
IA) (400x). This finding suggests that tacrolimus therapy effectively
inhibited fibrosis in IA (yellow arrows) after AMI. H) * vs. other
groups, p< 0.0001. All statistical analyses using one-way ANOVA,
followed by Tukey’s multiple comparison procedure. Symbols
(*, †, {) indicate significance (at 0.05 level) (n = 6 for each group).
The Scale bars in right lower corner represent 20 μm. HPF, high-
power field.Oxidative stress reaction of LV myocardium
The Oxyblot Oxidized Protein Detection Kit was
purchased from Chemicon (S7150). The oxyblot pro-
cedure was performed as previously described [19].
The DNPH derivatization was carried out on 6 μg of
protein for 15 minutes according to the manufac-
turer’s instructions. One-dimensional electrophoresis
was carried out on 12% SDS/polyacrylamide gel after
DNPH derivatization. Proteins were transferred to
nitrocellulose membranes which were then incubated
in the primary antibody solution (anti-DNP 1: 150)
for 2 h, followed by incubation in second antibody
solution (1:300) for 1 h at room temperature. The
washing procedure was repeated eight times within
40 minutes. Immunoreactive bands were visualized
by enhanced chemiluminescence (ECL; Amersham
Biosciences) which was then exposed to Biomax L
film (Kodak). For quantification, ECL signals were
digitized using Labwork software (UVP). For oxyblot
protein analysis, a standard control was loaded on
each gel.Histological study of fibrosis area
Masson's trichrome staining was used for studying fibro-
sis of LV myocardium. Three serial sections of LV myo-
cardium were prepared at 4 μm thickness by Cryostat
(Leica CM3050S). The integrated area (μm2) of fibrosis
in the slides was calculated using Image Tool 3 (IT3)
image analysis software (University of Texas, Health Sci-
ence Center, San Antonio, UTHSCSA; Image Tool for
Windows, Version 3.0, USA). Three selected sections
Figure 3 Gene and protein expressions of inflammatory and anti-inflammatory biomarkers on day 14 after AMI in infarcted area. A &
B) Notably higher mRNA expressions of plasminogen activator inhibitor (PAI)-1 and matrix metalloproteinase (MMP)-9 in AMI than in normal and
AMI + tacrolimus, and significantly higher in AMI + tacrolimus than in normal. * vs. other groups, p< 0.001. C) Significantly higher mRNA
expression of interleukin (IL)-10 in AMI + tacrolimus than in AMI and normal, and remarkably higher in AMI than in normal. * vs. other groups,
p< 0.0001. D) Remarkably higher mRNA expression of endothelial nitric oxide synthase (eNOS) in AMI + tacrolimus than in normal and AMI, and
markedly increased in normal than in AMI. * vs. other groups, p< 0.001. E) Substantially higher protein expression of eNOS in normal than in
AMI + tacrolimus and AMI, and notably higher in AMI + tacrolimus than in AMI. * vs. other groups, p< 0.01. F) Significantly higher protein
expression of nuclear factor (NF)-κB (p65) in AMI than in normal and AMI + tacrolimus. * vs. other groups, p< 0.01. G) Significantly higher protein
expression of tumor necrotic factor (TNF)-α in AMI than in normal and AMI + tacrolimus, and notably higher in AMI + tacrolimus than in normal. *
vs. other groups, p< 0.001. All statistical analyses using one-way ANOVA, followed by Tukey’s multiple comparison procedure. Symbols (*, †, {)
indicate significance (at 0.05 level).
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selected HPFs (400x) were analyzed in each section.
After determining the number of pixels in each fibrotic
area per HPF, the numbers of pixels obtained from the
three HPFs were summed. The procedure was repeated
in two other slides for each animal. The mean pixel
number per HPF for each animal was then determined
by summating all pixel numbers and dividing by 9. The
mean the integrated area (μm2) of fibrosis in LV myocar-
dium per HPF was obtained using a conversion factor of
19.24 (1 μm2 represented 19.24 pixels).Statistical analysis
Data are expressed as mean values ± SD or percentage (%).
The significance of group differences was evaluated with t-
test. Continuous variables among 3 groups were compared
using one-way ANOVA followed by Tukey’s multiple
comparison procedure. Statistical analysis was performed
using SAS statistical software for Windows version 8.2
(SAS institute, Cary, NC). A probability value< 0.05 was
considered statistically significant.Results
Transthoracic echocardiographic findings
Table 1 shows the echocardiographic findings prior to the
procedure and at day 14 after AMI induction. By day 0
prior to AMI induction, at both mitral valve and papillary
levels, the left ventricular end-diastolic dimension
(LVEDd), left ventricular end-systolic dimension (LVEDs),
left ventricular end-diastolic volume (LVEVd), left ven-
tricular end-systolic volume (LVEVs), left ventricular frac-
tional shortening (LVFS) and left ventricular ejection
fraction (LVEF) did not differ between animals without
treatment (MI-Only) and those with tacrolimus
treatment (MI-Tac). Additionally, these parameters at
mitral valve level were also similar between these
two groups of animals at day 14 after AMI induc-
tion. Furthermore, no difference was noted in LVEDs
and LVEVs at papillary level between these two
groups of animals at day 14 after AMI induction.
However, at papillary level, LVEDd and LVEVd were
significantly higher, whereas LVFS and LVEF were
significantly lower in MI-only group than in MI-Tac
group at day 14 after AMI induction. These findings
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modeling and preserved LV function following AMI.Figure 4 Expression levels of oxidative index and anti-oxidant
protein in infarcted area. A & B) The protein expression of
oxidative stress (n = 6). Oxidative index, protein carbonyls, was
substantially higher in AMI than in normal and AMI + tacrolimus,
and remarkably higher in AMI + tacrolimus than in normal. * vs.Measurement of infarct area at basal, middle, and apical
levels of left ventricle, the wall thickness at papillary level
of left ventricle and pathological findings using H. & E. stain
Upper Panel of Figure 1 shows the results of TTC stain-
ing by day 14 following AMI. As shown on the left panel
(Figure 1A), IA was notably larger in MI-only than in
MI-Tac group at basal, middle, and apical levels. Accord-
ingly, quantification of the IA (Figure 1B) demonstrated
significantly larger infarct at all three levels in the
former. Additionally, the wall thickness at papillary level
was significantly reduced in MI-only than in MI-Tac
(Figure 1C).
The lower panel of Figure 1 shows the results of H. & E.
stain of the IA at middle level of left ventricle by day 14
after AMI induction. As demonstrated on Figure 1D, 1E
and 1F, the IA was remarkably larger in MI-only than in
MI-Tac group. Accordingly, quantification of the IA
(Figure 1G) revealed significantly larger infarct at middle
level of left ventricle in the former.
These findings imply that, as compared with AMI
without treatment, therapy using tacrolimus markedly
limited infarct size and preserved infarcted wall thick-
ness of the animals on day 14 after AMI.other groups, p< 0.0001. C & D) Expression levels of anti-oxidant
proteins (n = 6). Protein expression of heme oxygenase (HO)-1 (C)
and NAD(P)H:quinone oxidoreductase (NQO)-1 (D) were notably
higher in AMI + tacrolimus than in AMI and normal, and significantly
higher in AMI than in normal. * vs. other groups, p< 0.005. All
statistical analyses using one-way ANOVA, followed by Tukey’s
multiple comparison procedure. Symbols (*, †, {) indicate
significance (at 0.05 level).Quantification of viable myocardium and fibrosis in
infarct area of LV myocardium
Figure 2A, 2B and 2C indicates troponin-I staining of
normal and IA for detecting viable myocardium, respect-
ively. The immunofluorescent imaging study demon-
strated that the distribution of troponin-I positive
myocardium in IA was markedly decreased in MI-only
group compared with that in the MI-Tac group on day
14 following AMI (Figure 2D).
To determine the impact of tacrolimus therapy on fi-
brosis in IA, Masson Trichrome staining was performed
(Figure 2E-G). As expected, the mean fibrotic area in IA
was remarkably higher in MI-only than in MI-Tac ani-
mals on day 14 after AMI induction (Figure 2H).The mRNA and protein expressions of inflammatory
and endothelial dysfunction markers, oxidative stress
and anti-inflammatory biomarkers
The mRNA expressions of plasminogen activator inhibi-
tor (PAI)-1 (Figure 3A) and matrix metalloproteinase
(MMP)-9 (Figure 3B), two indexes of inflammation, were
remarkably higher in MI-only compared to normal con-
trol animals (NC) on day 14 after AMI. However, these
two markers were significantly lower in the MI-Tac
group than in MI-only animals. These findings suggestthat tacrolimus plays an essential role in suppressing the
inflammatory reaction after AMI.
Interestingly, the mRNA expression of interleukin
(IL)-10 (Figure 3C), an anti-inflammatory marker, was
notably higher in MI-only than in NC animals at day
14 after AMI induction. This biomarker was further
increased in MI-Tac group compared with that in the
MI-only group. Possible explanation may be a triggering
of inherent self-protection in response to myocardial in-
jury that was further enhanced by the suppression of
immune/inflammatory reactions through tacrolimus
therapy.
The gene and protein expressions of endothelial nitric
oxide synthase (eNOS) (Figure 3D and E), an indicator
of the integrity of endothelial function/vasodilatation as
well as an anti-inflammatory contributor, were remark-
ably reduced in MI-only animals than in NC, but they
were substantially increased in MI-Tac animals com-
pared to their MI-only counterparts. Besides, the protein
Figure 5 mRNA and protein expressions of apoptosis and anti-apoptosis factors in infarcted area. The mRNA and protein expressions of
Bax (A & D) and caspase 3 (B & E) were notably higher in AMI than in normal and AMI + tacrolimus, and significantly higher in AMI + tacrolimus
than in normal. Conversely, the mRNA expression of Bcl-2 (C) was remarkably lower in AMI than in normal and AMI + tacrolimus, and notably
lower normal than in AMI + tacrolimus. Besides, the protein expression of Bcl-2 (F) was notably lower in AMI than in normal and AMI +
tacrolimus, and significantly lower in AMI + tacrolimus than in normal. * vs. other groups, p< 0.001. All statistical analyses using one-way ANOVA,
followed by Tukey’s multiple comparison procedure. Symbols (*, †, {) indicate significance (at 0.05 level) (n = 6 for each group).
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two indicators of inflammation, were significantly increased
in MI-only group than in NC, but they were markedly
reduced in MI-Tac group as compared with MI-only ani-
mals. Furthermore, oxidative stress (Figure 4A and B) was
significantly increased in MI-only group than in NC, but it
was markedly reduced in MI-Tac than in MI-only animals
by day 14 after AMI. Moreover, HO-1 (Figure 4C) and
NQO1 (Figure 4D), two anti-oxidative biomarkers, were re-
markably higher in MI-Tac animals than in MI-only and
NC animals, and significantly higher in MI-only group than
in NC animals on day 14 after AMI induction. These find-
ings further support that AMI-elicited vigorous inflamma-
tory reaction and oxidative stress, which cause further
myocardial damage and deterioration of heart function,
were effectively suppressed by tacrolimus.The mRNA and protein expressions of apoptotic and
anti-apoptotic biomarkers
Both mRNA and protein expressions of Bax (Figure 5A
and D) and caspase 3 (Figure 5B and E), two indicators of
apoptosis, were notably higher in MI-only group than in
NC, but were much lower in MI-Tac than in MI-only ani-
mals at day 14 after AMI induction. Conversely, both
mRNA and protein expressions of Bcl-2 (Figure 5C and
F), an index of anti-apoptosis, were remarkably lower in
MI-only group than in NC, but were significantly higher in
MI-Tac as compared with MI-only animals. Besides,TUNEL assay (Figure 6) showed substantially higher num-
ber of apoptotic nuclei in peri-IA in MI-only group than
in NC, but notably lower number in MI-Tac compared
with MI-only animals. These findings imply that tacroli-
mus suppressed myocardial damage through inhibiting
cellular apoptosis after AMI.The protein expressions of connexin43 (Cx43) and
α-smooth muscle actin (SMA) in IA
IHC staining demonstrated that the protein expres-
sion of Cx43 (Figure 7A), a component of gap junc-
tion for providing pathways with minimal resistance
for inter-cellular electrical coupling, was markedly reduced
in MI-only group than in NC, but was notably up-
regulated in MI-Tac compared with MI-only animals
by day 14 after AMI. In contrast to Cx43 expression,
the protein expression of α-SMA (Figure 7B), indicator of
cardiac fibroblast proliferation in response to AMI, was
substantially increased in MI-only animals than in NC, but
it was significantly attenuated in MI-Tac than in MI-only
group.Identification of inflammatory cells in IA
To evaluate whether CD40+ cells (Figure 8A-D) and
CD68+ cells (Figure 8E-H) (macrophage surface marker),
two surface markers of inflammatory cells, were up-regu-
lated in the IA, IHC and IHF staining were performed,
respectively. As anticipated, the numbers of CD40-
Figure 6 Detection of apoptotic nuclei in peri-infarcted area. A to C) showing the TUNEL examination of apoptotic nuclei (red arrows) in
peri-infarct area on day 14 after AMI. D) The number of apoptotic nuclei was notably higher in AMI than in normal and AMI + tacrolimus, and
significantly higher in AMI + tacrolimus than in normal. * vs. other groups, p< 0.001. All statistical analyses using one-way ANOVA, followed by
Tukey’s multiple comparison procedure. Symbols (*, †, {) indicate significance (at 0.05 level) (n = 6 for each group). Scale bars in right lower corner
represent 20 μm. HPF, high-power field (400x).
Figure 7 Protein expressions of connexin43 and α-smooth
muscle actin in infarcted area. A) Showing protein expression of
connexin43 (Cx43) remarkably lower in AMI than in normal and AMI
+ tacrolimus, and significantly lower in AMI + tacrolimus than in
normal (n = 6), * vs. other groups, p< 0.001. B) Demonstrating
protein expression of α-smooth muscle actin (SMA) remarkably
higher in AMI than in normal and AMI + tacrolimus, and markedly
increased in AMI + tacrolimus than in normal, * vs. other groups,
p< 0.0001. All statistical analyses using one-way ANOVA, followed
by Tukey’s multiple comparison procedure. Symbols (*, †, {) indicate
significance (at 0.05 level) (n = 6 for each group).
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in MI-only group than in NC. However, they were found
to be notably suppressed in MI-Tac animals than in those
with MI only.
Tentatively compared the effect of cyclosporine18 versus
tacrolimus therapy on attenuating the inflammatory,
apoptotic and oxidative-stress biomarkers in IA at day 14
after AMI
This study did not performed cyclosporine-treated AMI
group. Thus, we utilized the results from our recent re-
port [18] to compare the impact of cyclosporine and
tacrolimus therapy on ameliorating the inflammatory,
apoptotic and oxidative-stress responses after AMI. The
results in Table 2 exhibited the superior effects of tacro-
limus than that of cyclosporine on suppressing majority
of these biomarkers.
Discussion
The present study, which investigated the therapeutic
potential of tacrolimus via intra-coronary administra-
tion in a mini-pig AMI model, yielded several striking
implications. First, tacrolimus therapy markedly atte-
nuated myocardial infarct size. Second, remarkable in-
hibition of AMI-associated inflammatory responses
was noted following tacrolimus administration. Third,
cellular apoptotic episodes were substantially reduced
by adopting this agent in the setting of AMI. Finally,AMI-induced LV remodeling was significantly limited
and LV function was remarkably preserved utilizing
this therapy.
Previous studies [9,10,18,20] have shown that the de-
velopment of AMI quickly triggers inflammatory and
Figure 8 Identification of inflammatory cells in infarcted area. Immunofluorescence stain (A to C) showing the number of CD68+ stained
cells (yellow arrows), an indicator of macrophage, markedly increased in AMI than in normal and AMI + tacrolimus, and significantly higher in AMI
+ tacrolimus than in normal. * vs. other groups, p< 0.0001 (D). Blue color indicated DAPI stain for the nuclei. Immunohistochemical stain (E to G)
showing the number of CD40+ stained cells (red arrows), an index of inflammatory cells, substantially higher in AMI than in normal and AMI + tacrolimus,
and notably higher in AMI + tacrolimus than in normal. * vs. other groups, p< 0.0001 (H). All statistical analyses using one-way ANOVA, followed by
Tukey’s multiple comparison procedure. Symbols (*, †, {) indicate significance (at 0.05 level) (n=6 for each group). HPF = high-power field (400x). The Scale
bars in right lower corner represent 20 μm.
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complement cascade and enhance ROS generation.
Histopathological studies [9,11-13,18] have demonstrated
that inflammatory cells, including neutrophil, macrophages,
T and B cells, are recruited and accumulate in IA where
they secrete cytokines and produce antibodies specific to
myosin and actin. Therefore, myocardial damage from
AMI is often progressive and irreversible [11,13,18]. Oneimportant finding in the present study is the notable higher
inflammatory reactions as reflected in the enhanced gene
and protein expressions of pro-inflammatory cytokines
(PAI-1, MMP-9, TNF-α and NF-κB), oxidized protein, IHC
and IHF staining of inflammatory cells (CD40+ cells, CD68
+ cell) in AMI animals than in normal controls. In this
way, our findings reinforce those of the previous studies [9-
11,13,18,20].
Table 2 Comparison of the effect between cyclosporine
and tacrolimus on attenuating expressions of
inflammatory and oxidative-stress biomarkers in left






Caspase-3 mRNA 36% # 22%#
Bax mRNA 11% # 24%##*
Bcl-2 mRNA 75% " 200%""*
MMP-9 mRNA 11%# 29%##*
eNOS mRNA 36%" 160%""*
No. of CD40+ cells 44%# 22%#
Oxidative stress index 45%# 71%##*
* indicated the more effective response in Tacrolimus therapy as compared
with cyclosporine therapy on the changes of apoptotic, inflammatory and
oxidative-stress biomarkers.
† Results from recent reported in the Int J Cardiol (2011;147:79–87) (reference
no: 18).
MMP = matrix metalloproteinase; eNOS = endothelial nitric oxide synthase.
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compared to the animals with AMI without treatment,
those received tacrolimus therapy had significantly lower
levels of oxidative stress and inflammatory responses.
These findings imply that tacrolimus possesses potent
immunosuppressive property [15,16] against inflamma-
tory reaction and ROS generation. More importantly,
the results of present study, in addition to supporting
the results of previous studies [9,11,13,18,20], could, at
least in part, account for the reduction in infarct size, at-
tenuation of LV remodeling, and preservation of LV
function following tacrolimus administration.
Another important finding in the present study is that
AMI-associated enhancement in apoptosis at both mo-
lecular and cellular levels, as demonstrated in the ele-
vated pro-apoptotic gene and protein expressions (Bax,
caspase 3) and increased number of apoptotic nuclei on
TUNEL assay, was markedly reduced after tacrolimus
treatment. Consistently, the suppressed gene and protein
expressions of Bcl-2, an anti-apoptotic index, in AMI
animals without treatment were notably preserved fol-
lowing tacrolimus treatment. These findings support
that tacrolimus therapy, in addition to being anti-
inflammatory, also effectively contributes to inhibition of
AMI-related cellular apoptosis [18,20,21].
Pathologically, TTC staining demonstrated remarkably
reduced infarct size at basal, middle, and apical levels as
well as significantly increased LV thickness in animals with
tacrolimus treatment compared to those without. More-
over, myocardial viability, as reflected in the positivity of
troponin-I staining, was notably preserved in IA, whereas
the fibrotic area on Masson Trichrome staining and cardio-
fibroblast proliferation (i.e. α-SMA) in IA were substantiallyreduced in animals having received tacrolimus. Further-
more, protein expression of Cx43 [19] was notably pre-
served in animals with tacrolimus treatment, suggesting
preservation of electrical coupling between cardiomyocytes
following AMI. Taking together, these findings may explain
the significant attenuation of LV remodeling (i.e. LVEDd &
LVEVd) and preservation of LV function (i.e. LVFS and
LVEF) in animals with tacrolimus treatment.
Despite of the previous studies have emphasized
that the tacrolimus is a more potent immunosuppres-
sant compared to cyclosporine for preventing long-
term graft failure [16], there has no available data to
address which one of these two drugs is better for
preserving myocardium from ischemia-related damage
in a setting of AMI. We, therefore, compared the
effects of these two drugs by using the information
from our recent report [18] and the results of the
current study on inhibiting the inflammatory, apop-
totic and oxidative-stress responses after AMI. The
results (Table 2) displayed the superior effects of
tacrolimus to cyclosporine on suppressing the major-
ity of these biomarkers. In this way, the results from
the analyses were comparable with the reports from
the previous study [16].
Study limitations
This study has limitations. First, the therapeutic benefits of
cyclosporine, a calcineurin inhibitor similar to tacrolimus,
in limiting myocardial infarction, preserving LV function,
and improving clinical outcome have been previously
reported [17,18], however, since we did not include the
positive control group of cyclosporine in the present study,
whether the mechanisms of tacrolimus treatment involved
in the protection of myocardium from ischemic injury are
similar to those of cyclosporine therapy remains unclear.
Further experimental investigation comparing the effects of
these immunosuppressants on the progression of myocar-
dial infarction, therefore, would strengthen the significance
and interest of the present study. Second, the mechanisms
of tacrolimus therapy on reducing the inflammation and
cellular apoptosis were not explored in the current
study. However, previous study has shown that tacro-
limus therapy suppressed T cell activation through
the inhibition of NF-AT activation which, in turn,
attenuated inflammatory reaction [14,15].
Conclusion
This experimental study demonstrated that AMI induc-
tion through LAD ligation in a mini-pig model initiated a
cascade of inflammatory processes and generation of oxi-
dative stress which, in turn, caused further myocardial in-
jury. Intra-coronary administration of tacrolimus markedly
attenuated inflammatory reaction, limited the infarct size,
inhibited LV dilatation and remodeling, as well as
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fusion therapy.
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